02/02/2016

EISAI AND ESTEVE SIGN NEW AGREEMENT TO CO-PROMOTE ANTI-EPILEPSY DRUG FYCOMPA® (PERAMPANEL) IN SPAIN

Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (≥12 years) with idiopathic generalised epilepsy (IGE) in Spain in early 2016.

Eisai enter into a new agreement with Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to co-promote Fycompa® (perampanel) in Spain from February 2016. Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (≥12 years) with idiopathic generalised epilepsy (IGE) in Spain in early 2016. Perampanel is also indicated in Spain for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

"We are pleased to further strengthen our relationship with Esteve under this new agreement to co-promote perampanel. This collaboration will ensure that we maximise access to our products for people with epilepsy [per indication] in Spain," comments Gary Hendler, President and CEO, Eisai EMEA.

"The new collaboration with Eisai under the agreement to co-promote perampanel in Spain will further consolidate our presence in neurology, one of our priority areas, and allow us to continue our efforts to bring epilepsy treatments to patients who need them," says Joe Sullivan, Managing Director of Esteve Farma

Epilepsy is a common neurological condition that causes recurrent seizures in the brain. It is usually diagnosed in children and people over 65 years of age, although it can affect anyone.2 Currently, up to 22,000 people are diagnosed with epilepsy each year in Spain, of whom around one third have seizures that are not completely controlled by their anti-epileptic therapy.

The new agreement with Esteve in Spain demonstrates Eisai's commitment in the therapeutic area of epilepsy and further exemplifies the company's contribution to addressing the diversified needs of and increasing the benefits provided to patients and their families as shown by its human health care mission.


You can follow ESTEVE on Twitter at this link: twitter.com/esteve_news.

Related Information

Last news

  • THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’

    Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...

    read more
  • PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES

    Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...

    read more
  • ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER

    ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.